NCT02629874View on ClinicalTrials.gov

PK/PD of EA-230 During Endotoxemia

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

December 31, 2015

Conditions
EndotoxemiaSystemic Inflammatory Response
Interventions
DRUG

EA-230

at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.

DRUG

Endotoxin

at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously

DRUG

Placebo

Trial Locations (1)

6525 GA

Intensive care, research unit, Radboud University Medical Centre, Nijmegen

All Listed Sponsors
collaborator

Exponential Biotherapies Inc.

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT02629874 - PK/PD of EA-230 During Endotoxemia | Biotech Hunter | Biotech Hunter